Bleeding rates are steadily dropping after both elective and emergent percutaneous coronary intervention (PCI), according to registry data published in the May 22, 2012, issue of the Journal of the ...

The 2011 focused update was published online March 28, 2011, ahead of print in the Journal of the American College of Cardiology and Circulation. The writing committee, led by R. Scott Wright, MD, of ...

Characteristics of STEMI Reperfusion Systems Identified Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor ...

Coronary syndromes vary in severity, ranging from unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), to ST-segment elevation myocardial infarction (STEMI), the most severe ...

(1) How was this issue identified? Starting in quarter 1 2007, we noticed the high rate of excess dosing for heparin on our ACTION site reports compared to national rates. (2) What did you do to ...

Despite advances in treatment, acute coronarysyndromes (ACS), which consist mainly of ST-segmentelevation myocardial infarction (STEMI) andunstable angina (UA)/non-STEMI (NSTEMI), presentan enormous ...

In draft guidance published today for consultation, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for preventing blood clots in people who have had a heart attack as a ...

Oral anti-platelet therapy Effient (prasugrel) has been added to the updated clinical practice guidelines as a class I recommended treatment option for patients undergoing Percutaneous Coronary ...

Final draft guidance published today (16 September) by NICE confirms its previous positive draft recommendation for ticagrelor (Brilique, Astrazeneca). The draft guidance recommends ticagrelor within ...

Individuals with diabetes and acute coronary syndromes such as a heart attack or unstable angina have an increased risk of death at 30 days and one year after ACS, compared with ACS patients without ...

CHICAGO, IL — A small, single-center analysis suggests that it may be time to increase the recommended maximum, weight-based unfractionated-heparin bolus and infusion doses for patients with ACS so as ...